Caplight Directory>Companies>Eliksa Therapeutics-preview>Eliksa


Eliksa Therapeutics

Eliksa Therapeutics

Private
Doylestown, PennsylvaniaHealthcare & Life Scienceshttp://www.eliksa.com

Last Round

Seed

Jul 19, 2022

Company Overview

Eliksa Therapeutics is a biotechnology company that develops novel medicines for a range of debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicineEpidermolysis Bullosabiologic eye dropEB treatmentamniotic membrane allograftrare disease treatmentorphan diseaseocular repairamniotic fluid therapycorneal abrasionclinical-stage biotechbiologicswound caretissue allograftneurotrophic keratitis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eliksa Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Eliksa Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedJul 19, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Armen Karamanian

Co-Founder CEO

Founding Team

Eliksa Therapeutics Investors

Notable investors and investment history

InvestorRounds
Ben Franklin Technology Partners of Southeastern PennsylvaniaSeed
Militia Hill VenturesSeed
JVS Philadelphia Fund for WomenSeed
View all Investors

Eliksa Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eliksa Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eliksa Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDoylestown, Pennsylvania
Employee Range6
Year Founded2021
Last FundingJul 19, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.